DOI: To evaluate the efficacy of a long-acting preparation of medroxyprogesterone acetate for hot flash management, 3 men receiving androgen ablation therapy for prostate cancer and 15 women with a history of breast cancer were treated as part of clinical practice with three biweekly intramuscular injections of 500 mg depomedroxyprogesterone
You are less likely to
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone
As cyproterone is a recognised treatment in prostate cancer, and its use could interfere with hormonal therapy, medroxyprogesterone could be considered to be the standard treatment for hot flushes in men
Hot flashes are one of the most common side effects of hormonal therapy, which lowers testosterone and androgens
This study evaluated the effectiveness of parenteral medroxyprogesterone acetate (MPA) in reducing the frequency and severity of these hot flashes
Conditions that may
However, the hormonal treatments cyproterone and medroxyprogesterone were significantly more effective than venlafaxine
breast tenderness and growth of breast tissue (called gynecomastia) loss of muscle and physical strength
1016/j
Hot flushes are common and bothersome symptoms in men with prostate cancer and those taking anti-androgen treatment, and reduce quality of life
Irani J, Salomon L, Oba R, et al
)
Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of locally advanced and metastatic prostate cancer
Medroxyprogesterone also comes as an injection that's used as contraception
Men with prostate cancer who reported having significant hot flushes during androgen suppression treatment had a better hormonal response with cyproterone and medroxyprogesterone compared with More than 3 million men are living with or have survived prostate cancer
Androgen deprivation therapy (ADT) is the first line of treatment for advanced-stage prostate
Literature search: The CINAHL®, Embase®, PsycINFO®, PubMed®, and Scopus® databases were used to identify randomized controlled trials (RCTs) and quasiexperimental studies
1984;2:1207-8
loss of fertility, radiation-induced enteropathy, osteoporosis, gynaecomastia, fatigue, and hot flushes
Few treatments are available and some are avoided Hot flashes result from chemotherapy, induced menopause or hormonal treatment
Purpose: Survivors of estrogen receptor-expressing breast cancer generally do not receive estrogen-based therapy for menopausal symptoms due to concern for provoking recurrence of disease